Cutaneous hypersensitivity reactions to inhibitors of cyclooxygenase-2 - Results from 307 oral provocation tests and review of the literature

Allergy and Clinical Immunology International

Volumn 19, Issue 2, 2007, Pages 44-49

  Sánchez Borges, Mario ^a,b   Capriles Hulett, Arnaldo ^a   Caballero Fonseca, Fernan ^a  

^a Centro Medico Docente La Trinidad   (Venezuela)

^b POBA International   (United States)

Author keywords

Angioedema; Cyclooxygenase 2; NSAIDS; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; ETORICOXIB; GLAFENINE; IBUPROFEN; IMMUNOGLOBULIN E; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ROFECOXIB; SULINDAC; TIAPROFENIC ACID; VALDECOXIB;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ANGIONEUROTIC EDEMA; ASTHMA; ATOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME INHIBITION; ERYTHEMA MULTIFORME; FEMALE; HUMAN; IN VITRO STUDY; LICHENOID ERUPTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; MEDLINE; PHOTOALLERGY; PREVALENCE; PROVOCATION TEST; PSEUDOPORPHYRIA; PUSTULOSIS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SKIN MANIFESTATION; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

EID: 34250311697     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: 10.1027/0838-1925.19.2.44     Document Type: Review

References (53)

1. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. How safe are COX-2 inhibitors in NSAID-sensitive subjects with cutaneous reactions? Allergy Clin Immunol Int 2003; 15:110-113
2. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/NSAID intolerant patients. Comparison of nimesulide, meloxicam and rofecoxib. J Asthma 2004; 41:67-75
3. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-786
4. Looney Y, O'Shea A, O'Dwyer R. Severe bronchospasm after parenteral parecoxib: Cyclooxygenase-2 inhibitors: Not the answer yet. Anesthesiology 2005; 102:473-475
5. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Adverse reactions to selective cyclooxygenase-2 inhibitors (coxibs). Am J Ther 2004; 11:494-500
6. Fye KH, Crowley E, Berger TG. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol 2001; 45:300-302
7. Schneider F, Meziani F, Chartier C. Fatal allergic vasculitis associated with celecoxib. Lancet 2002; 359: 852-853
8. Ernst EJ, Egge JA. Ceecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy 2002; 22: 637-640
9. Verbeiren S, Morant C, Charlanne M. Celecoxib induced toxiderma with positive patch test. Ann Dermatol Venereol 2002; 129:203-205
10. Friedman B, Orlet HK, Still JM. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J 2002; 95:1213-1214
11. Berger P, Dwyer D, Corallo CE. Toxic epidermal necrolysis after celecoxib therapy. Pharmacotherapy 2002; 22:1193-1195
12. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003; 23: 551-553
13. Marques S, Milfied B, Foulc P, Barbarot S, Cassagnan E, Stalder JF. Severe cutaneous drug reactions to celecoxib (Celebrex). Ann Dermatol Venereol 2003; 130:1051-1055
14. Talhari C, Lauceviciute I, Enderlein E, Ruzicka T, Homey B. COX-2 selective inhibitor valdecoxib induces severe allergic skin reactions. J Allergy Clin Immunol 2005; 115:1089-1090
15. Giglio P. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J 2003; 96:320-321
16. Perna AG; Woodruff CA, Markus RF, Hsu S. Toxic epidermal necrolysis as a complication of treatment with celecoxib. Dermatology Online J 2003; 9:25
17. Schmutz JL, Barbaud A, Trechot P. Toxic epidermal necrolysis and celecoxib (Celebrex). Ann Dermatol Venereol 2004; 131:107
18. Yang CC, Lee JY, Chen WC. Acute generalized exanthematous pustulosis caused by celecoxib. J Formos Med Assoc 2004; 103:555-557
19. Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: A case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology 2004; 209:53-56
20. Byerly FL, Nelson KC, Granko RP, Morrell DS, Cairns BA. Valdecoxib associated acute generalized exanthematous pustulosis. Burns 2005; 31: 383-387
21. Markus R, Reddick ME, Rubenstein MC. Rofecoxib-induced pseudoporphyria. J Am Acad Dermatol 2004; 50:647-647
22. Abu-Shraie NA, Alfadley AA. Lichenoid drug eruption probably associated with rofecoxib. Ann Pharmacother 2004; 38:795-798
23. Yazici AC, Baz K, Ikizoglu G, Kokturk A, Uzumlu H, Tataroglu C. Celecoxib-induced photoallergic drug eruption. Int J Dermatol 2004; 43: 459-461
24. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. The multiple faces of nonsteroidal anti-inflammatory drug hypersensitivity. J Inv Allergol Clin Immunol 2004; 14:329-334
25. Sánchez-Borges M, Capriles-Hulett A, Capriles-Behrens E, Fernández-Caldas E. A new triad: sensitivity to aspirin, allergic rhinitis and severe allergic reaction to ingested aeroallergens. Cutis 1997; 59:311-314
26. Sánchez-Borges M, Suárez-Chacón R, Capriles-Hulett A, Caballero-Fonseca F. An update on oral anaphylaxis from mite ingestion. Ann Allergy Asthma Immunol 2005; 94:216-222
27. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase-2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005; 95:154-158
28. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999; 96:7563-7568
29. Espinola S, Mora D, Brizuela M. Intolerancia al rofecoxib en pacientes intolerantes a AINEs (Intolerante to rofecoxib in patients with intolerante to NSAIDs). Arch Alergia Immunol Clin 2001; 32:121-123
30. Zollner TM, Ahlbach S, Kauffman R. Tolerability of a selective cyclooxygenase-2 inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents. Dtsch Med Wochenschr 2001; 126:386-388
31. Asero R. Tolerability of rofecoxib. Allergy 2001; 56:916-917
32. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001; 87:201-204
33. Nettis E, Di PR, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 88:331-334
34. Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89:63-66
35. Valero A, Baltasar M, Enrique E, Pau L, Dordal T, Cisteró A, Martí E, Picado C. NSAID-sensitive patients tolerate rofecoxib. Allergy 2002; 57:1214-1215
36. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002; 32: 397-400
37. Kruse R, Ruzicka T, Grewe M. Intolerance reaction due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation test in patients with NSAID hypersensitivity. Acta Derm Venereol 2003; 83:183-185
38. Muñoz-Bellido FJ, Terron M, Leon A. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 2003; 58:1072-1075
39. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, Romano A. Tolerability of rofecoxib in patients with adeverse reactions to nonsteroidal anti-inflammatory drugs: A study of 216 patients and literature review. Int Arch Allergy mImmunol 2003; 132:82-86
40. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, Romagnani S. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004; 59:1133-1134
41. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: Comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004; 41:67-75
42. Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadomia P, Dama AR. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol (Paris) 2004; 36:215-218
43. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94:34-38
44. Ahlbach S, Usadel KH, Kaufmann R, Boehncke WH. The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudoallergic reactions to nonsteroidal anti-inflammatory drugs. Med Kiln (Munich) 2003; 98:242-244
45. Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C, Volpetti S, Romano A. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 137:145-150
46. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 2005; 42:127-131
47. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628-1635
48. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Drug Safety 2001; 24:239-247
49. Zembowicz A, Nastalerz L, Setkowicz M, Radziszewski N, Szczeklik A. Safety of cyclooxygenase-2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to non-steroidal anti-inflammatory drugs. Arch Dermatol 2003; 139:1577-1582
50. Serrano C, Valero A, Picado C. Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: A case report. J Inv Allergol Clin Immunol 2005; 15:156-157
51. Sánchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000; 84: 101-106
52. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Enhanced Allergic Response to Blomia tropicalis Allergens in NSAID-sensitive Subjects with Cutaneous Reactions. J Allergy Clin Immunol 2006; 117:S228
53. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351:1707-1709